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Abstract
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treatment of arterial 
hypertension and cardiovascular diseases. Our objective was to study whether captopril is able to attenuate the cardiac 
inflammatory process associated with arterial hypertension.
Methods: Left ventricle mRNA expression and plasma levels of pro-inflammatory (interleukin-1β (IL-1β) and IL-6) and 
anti-inflammatory (IL-10) cytokines, were measured in spontaneously hypertensive rats (SHR) and their control 
normotensive, Wistar-Kyoto (WKY) rats, with or without a 12-week treatment with captopril (80 mg/Kg/day; n = six 
animals per group). To understand the mechanisms involved in the effect of captopril, mRNA expression of ACE, 
angiotensin II type I receptor (AT1R) and p22phox (a subunit of NADPH oxidase), as well as NF-κB activation and 
expression, were measured in the left ventricle of these animals.
Results: In SHR, the observed increases in blood pressures, heart rate, left ventricle relative weight, plasma levels and 
cardiac mRNA expression of IL-1β and IL-6, as well as the reductions in the plasma levels and in the cardiac mRNA 
expression of IL-10, were reversed after the treatment with captopril. Moreover, the mRNA expressions of ACE, AT1R and 
p22phox, which were enhanced in the left ventricle of SHR, were reduced to normal values after captopril treatment. 
Finally, SHR presented an elevated cardiac mRNA expression and activation of the transcription nuclear factor, NF-κB, 
accompanied by a reduced expression of its inhibitor, IκB; captopril administration corrected the observed changes in 
all these parameters.
Conclusion: These findings show that captopril decreases the inflammation process in the left ventricle of 
hypertensive rats and suggest that NF-κB-driven inflammatory reactivity might be responsible for this effect through 
an inactivation of NF-κB-dependent pro-inflammatory factors.
Background
The spontaneously hypertensive strain of the Wistar-
Kyoto rat, that is the spontaneously hypertensive rat
(SHR), provides a useful experimental model that devel-
ops hypertension and is characterized by structural and
functional changes in the heart [1]. The heart to body
mass ratio or the relative weight of the left ventricle, use-
ful indices of ventricular hypertrophy at the organ level,
have been found by several authors to be elevated in SHR
[2-4]. This cardiac hypertrophy is correlated with an
inflammatory process, suggesting that inflammation
could be a key event in cardiovascular complications in
hypertensive animals [5,6]. We and other authors have
shown an increase in the heart inflammatory process in
SHR [7], in L-NAME-induced arterial hypertension [8],
as well as in hypertension induced by angiotensin II or
aldosterone [9,10].
Angiotensin II (ANGII), the key effector of the renin-
angiotensin system (RAS), plays an important role in the
regulation of blood pressure, and there is accumulating
evidence to indicate that ANGII is also capable of induc-
ing an inflammatory response in the cardiac tissue
through the activation of the nuclear factor κB (NF-κB)
[11-13]. Recent studies have also described the role of
interleukin-10 (IL-10) in ANGII-induced expression of
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[14].
Angiotensin-converting enzyme (ACE) inhibitors have
long been known to be effective in the reduction of blood
pressure and in the regression of left ventricular hyper-
trophy both in humans with essential hypertension [15]
and in different animal models of arterial hypertension,
such as SHR [16] and NO-deficient hypertensive rats
[17]. Moreover, the treatment with ACE inhibitors
reversed the increase in the production of superoxide
anions and the activation of NF-kB system, as well as the
elevated expression of pro-inflammatory cytokines, in
aortas of rat with reduced NO synthesis [18] and in a rab-
bit model of atherosclerosis [19]. Also, a reduction in the
circulating levels of intercellular adhesion molecule-1
(ICAM-1) has been observed in hypertensive patients
[20] and in human aortic endothelial cells [21] after the
treatment with an ACE inhibitor.
Captopril is a widely used ACE inhibitor for treatment
of arterial hypertension and cardiovascular diseases
[22,23]. It has been shown to express immune regulating,
antioxidant and anti-inflammatory properties [24]. Thus,
captopril has been proved to be beneficial in experimen-
tal autoimmune encephalomyelitis [25], adriamycin-
induced nephropathy [26], arthritis [27] and experimen-
tal rat colitis [28]. Captopril suppresses the inflammation
in endotoxin-induced uveitis in rats [29]; improves oxida-
tive stress in the kidney of L-NAME-treated rats [30], and
increases the antioxidant defenses in mouse tissues [31].
In addition, the treatment with captopril produces a
decrease in the left ventricle inflammatory cell infiltra-
tion in angiotensin II and aldosterone-salt-induced
hypertension [32].
In the present work, we explore the effect of captopril
on the cardiac inflammatory process associated with
arterial hypertension. In particular, we have measured
arterial blood pressure, heart rate, cardiac hypertrophy,
as well as plasma levels and heart mRNA expression of
pro-inflammatory (IL-1β and IL-6) and anti-inflamma-
tory (IL-10) cytokines in SHR, with or without a chronic
administration of captopril. In addition, the mRNA
expression of ACE, angiotensin II type I receptor (AT1R),
p22phox subunit of NADPH oxidase, and the expression
and activation of NFκB, has also been measured in the
left ventricles of these animals, in order to know the
mechanism(s) involved in the anti-inflammatory effects
of captopril.
Methods
Animals, treatments, heart tissue sampling and 
measurements in plasma
This study was conducted in accordance with the
National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals. Normotensive, male
Wistar-Kyoto (WKY) and spontaneously hypertensive
rats (SHR) aged 18-20 weeks were obtained from Harlan
IBERICA, S.A. (Barcelona, Spain). Rats were housed at a
temperature of 22-24°C in individual cages and freely fed
a regular pellet diet. They were divided into four groups
of six animals each: (1) WKY (control group), (2) SHR
(untreated), (3) WKY treated with captopril (WKYCPT),
and (4) SHR treated with captopril (SHRCPT). Captopril
(CPT) was administered during 12 weeks as a dose of 80
mg/kg/day dissolved in the drinking water, the concentra-
tions being adjusted according to daily water consump-
tion and body weight in order to ensure correct dosage.
Diastolic and systolic blood pressures, as well as the heart
rate, were measured after the experimental period using
the non-invasive and indirect method of tail-cuff occlu-
sion in conscious animals using a NIPREM 645 pressure
recorder (Cibertec, Barcelona, Spain). Body weight was
determined on the same day that blood pressure was
measured. At the end of the experimental period, all ani-
mals were fasted overnight before killing. They were
anesthetized with pentobarbital (50 mg/kg i.p.) and blood
samples were obtained by cardiac puncture and collected
into tubes containing lithium heparin. Rats were killed by
decapitation, then the heart was quickly removed and
washed out with ice-cold 0.9% saline solution, and the left
ventricle was dissected and weighed to calculate the rela-
tive left ventricle weight/body weight (LVW/BW). Sam-
ples of the left ventricle were frozen and stored at -70°C
until use. To minimize diurnal variations, rats were rou-
tinely killed between 09:00 and 10:00 hours.
Plasma was separated by low-speed centrifugation at
1500 g and at 4°C for 30 min. IL-1β, IL-6 and IL-10 were
measured in plasma using a quantitative sandwich
enzyme immunoassay (commercial ELISA kits). Rat-spe-
cific monoclonal antibodies of each cytokine were pre-
coated onto microplates (Pierce Biotechnology, Rockford,
IL).
NF-κB activity
Left ventricles from all experimental animal groups were
used for determination of NF-kB activity. Nuclear
extracts from left ventricles were obtained using com-
mercially available nuclear extraction kits (Active Motif,
Madrid, Spain) following the manufacturer's recommen-
dations. P65 NF-κB activity was assessed with a tran-
scription factor assay kit according to the manufacturer's
instructions (TransAM NF-kB p65 kit, Active Motif,
Madrid, Spain), which can measure the binding of acti-
vated p65 NF-kB to its consensus sequence attached to a
microwell plate. Antibodies for the activated form of the
p65 subunits of NF-κB were included in the assay.
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reaction (RT-PCR)
Reverse transcription (RT) and real-time PCR was ana-
lyzed as previously reported [8]. Whole RNA was
extracted from frozen left ventricle rats after homogeni-
zation with 1 mL of Tripure Isolation Reagent (Roche
Diagnostics Corp., Indianapolis, USA) as described by
Chomczynski and Sacchi [33]. RT was carried out in a
final volume of 100 μL using a Ready-To-Go You-Prime
First-Strand Beads (GE Healthcare, Madrid, Spain)
according to the supplier's protocol. After RT, cDNA was
purified using a commercial kit (GFX DNA purification
kit, GE Healthcare, Madrid, Spain). cDNA was then
diluted in sterile water and used as template for the
amplification by the polymerase chain reaction (PCR).
The specific mRNA sequences were amplified using the
following pairs of primers: (from 5' to 3'):
IL-1β forward: GAGG CTGACAGACCCCAAAAGAT.
IL-1β reverse: GCACGAGGCATTTTTGTTGTTCA
(product size 336 bp).
IL-6 forward: GAAATACAAAGAAATGATGGAT-
GCT.
IL-6 reverse: TTCAAGATGAGTTGGATGGTCT (310
bp).
p22phox forward: GCTCATCTGTCTGCTGGAGTA,
p22phox reverse: ACGACCTCATCTGTCACTGGA
(434 bp);
ACE forward: CAAAGTTCACTTGCTTCTTGG.
ACE reverse: TACTGTAAATGGTGCTCATGG (262
bp).
AT1R forward: CACCTATGTAAGATCGCTTC.
AT1R reverse: GCACAATCGCCATAATTATCC (445
bp).
p65 NF-κB forward: CCTAGCTTTCTCTGAACTG-
CAAA
p65 NF-κB reverse: GGGTCAGAGGCCAATAGAGA
(71 bp).
IκB forward: TGGCTCATCGTAGGGAGTTT
IκB reverse: CTCGTCCTCGACTGAGAAGC (68 bp)
GAPDH forward: GCCAAAAGGGTCATCATCTC-
CGC.
GAPDH reverse: GGATGACCTGCCCACAGCCTTG
(319 bp).
Each specific gene product was amplified by real-time
PCR using Sybergreen TM reactions and an ABI PRISM
7000 Sequence Detection System (PE Applied Biosys-
tems, Foster City, CA). Amplification data were collected
by the sequence detector and analysed with sequence
detection software. For each assay, a standard curve was
constructed using increasing amounts of cDNA. In all
cases, the slope of the curves indicated adequate PCR
conditions (slope 3.2-3.4). The RNA concentration in
each sample was determined from the threshold cycle
(Ct) values and calculated with sequence detection soft-
ware supplied by the manufacturer. The quantitative fold
changes in mRNA expression were determined as relative
to GAPDH mRNA levels in each corresponding group
and calculated using the 2-ΔΔCT method.
Calculations and statistical analysis
The GraphPad Instat statistical program was used to ana-
lyze the data. All results were subjected to one-way analy-
sis of variance (ANOVA) and represent means ± S.E.M.
of six animals per experimental group. Differences in
mean values between groups were assessed by Tukey-
Kramer's test and considered statistically different at P <
0.05.
Reagents
Unless otherwise specified, all reagents were obtained
from Sigma Chemical (Madrid, Spain). Primers for RT-
PCR analysis were synthesized by Tib Molbiol (Berlin,
Germany). Captopril was obtained from Roig-Farma
(Barcelona, Spain).
Results
Body weight, left ventricle weight, blood pressure and 
heart rate
No significant differences in body weights were observed
among all four groups of animals at the end of the experi-
mental period. The LVW/BW ratio (as an index of ven-
tricular hypertrophy), as well as diastolic and systolic
blood pressures and heart rate, were significantly
increased in hypertensive animals (SHR) when compared
with control, WKY rats. The treatment with captopril
reversed these parameters back to normal values in SHR,
and no effect of CPT was observed in WKY rats (Table 1).
Plasma levels and cardiac mRNA expression of cytokines
Plasma levels of IL-1β and IL-6 were significantly higher
in SHR when compared with control, normotensive WKY
rats (54% and 34%, respectively). The treatment with cap-
topril was able to reverse these increases, reaching values
similar to those observed in WKY rats. On the other
hand, plasma levels of IL-10 were diminished in hyper-
tensive rats (54%), this reduction being attenuated after
treatment with captopril. No changes were observed
between WKY and WKYCPT groups (Table 2). In addi-
tion, SHR showed a significant increase in the left ventri-
cle mRNA expression of IL-1β and IL-6 together with a
reduction in IL-10 when compared with WKY (15.1 ± 1.3
relative expression (RE) and 29.5 ± 2.8 RE for WKY and
SHR, respectively, for IL-1β, p < 0.01; 192 ± 16.4 RE and
723 ± 85 RE for WKY and SHR, respectively, for IL-6, p <
0.001; 80.5 ± 2.1 RE and 42.3 ± 0.9 RE for WKY and SHR,
respectively, for IL-10, p < 0.001). After the treatment
with captopril, these changes were prevented and the
mRNA expression in SHR became 13.7 ± 2.2 RE, 219 ± 22
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tively. In contrast, no changes were observed in the
expression of these cytokines in WKY rats treated with
captopril (Figure 1).
Expression of ACE, AT1 receptor (AT1R) and p22phox in the 
heart
Figure 2 shows ACE, AT1R and p22phox mRNA expres-
sions in left ventricles from all groups of rats. The expres-
sion of these tree molecules was significantly increased in
SHR over control, WKY rats (13.6 ± 0.4 RE and 21.9 ± 1.6
RE for WKY and SHR, respectively, for ACE, p < 0.01; 1.3
± 0.1 RE and 4.3 ± 0.6 RE for WKY and SHR, respectively,
for AT1R, p < 0.001; 311 ± 16 RE and 618 ± 58 RE for
WKY and SHR, respectively, for p22phox, p < 0.001). The
administration of captopril to hypertensive rats was able
to prevent the abnormally high values for these parame-
ters and maintained their expressions at levels similar to
those from the control group (10.9 ± 1 RE, 2.2 ± 0.3 RE
and 403 ± 18 RE for ACE, AT1R and p22phox, respec-
tively). No effects were observed in WKY rats treated
with captopril.
Heart mRNA expression of the system NF-κB/IκB
SHR showed a significant increase in the expression of
NF-κB when compared with WKY rats (21.8 ± 2.5 RE and
68.5 ± 7.5 RE for WKY and SHR, respectively, p < 0.001),
and captopril prevented this alteration (29.5 ± 2.4 RE for
SHR treated with captopril). On the other hand, when
mRNA expression of IβB was determined, a significant
decrease was observed in hypertensive animals (45.5 ±
1.7 RE and 19.5 ± 1.5 RE, for WKY and SHR, respectively,
p < 0.001), and the treatment of captopril was also able to
inhibit this observation (50.0 ± 2.2 RE for SHR treated
with captopril). Once again, no differences were observed
between captopril-treated or untreated WKY rats (Figure
3).
NF-κB activation
We further investigated the effect of captopril on cardiac
NF-κB activation. We found a 49% increase in left ventri-
cle NF-κB p65 binding activity in SHR compared with
WKY rats (0.79 ± 0.06 optical density (OD) and 1.18 ±
0.11 OD for WKY and SHR, respectively, p < 0.001). This
activation was significantly inhibited in SHR treated with
captopril (0.61 ± 0.05 OD for SHR treated with captopril).
No changes were observed between WKY and WKY
treated with captopril (Figure 4).
Discussion
The aim of the present work was to explore the effect of
captopril, a known ACE inhibitor, on the cardiovascular
inflammatory process associated with arterial hyperten-
sion. In the current study we demonstrate, for the first
time, that treatment with captopril reverses the observed
increase in the gene expression of pro-inflammatory
cytokines (IL-1β and IL-6), and the decrease in the gene
expression of anti-inflammatory cytokines (IL-10), in the
left ventricle of SHR; this effect is mediated by an inacti-
Table 1: Final body weight, left ventricle weight/body weight ratio (LVW/BW), blood pressures, and heart rate in WKY, SHR, 
WKY treated with captopril (WKYCPT), and SHR treated with captopril (SHRCPT).
Parameter WKY SHR WKYCPT SHRCPT
Body weight (g) 391 ± 3 396 ± 10 372 ± 8 385 ± 16
LVW/BW (mg/g) 2.06 ± 0.08 2.68 ± 0.04*** 1.93 ± 0.05### 2.01 ± 0.09###
Final DBP (mm Hg) 114 ± 1 207 ± 0.6*** 115 ± 1### 117 ± 0.7###
Final SBP (mm Hg) 140 ± 0.9 231 ± 0.8*** 139 ± 1.1### 138 ± 0.8 ###
Heart rate (beats/min) 342 ± 1.1 392 ± 2.6*** 339 ± 1.8### 339 ± 1.7 ###
DBP, diastolic blood pressure; SBP, systolic blood pressure. Values are expressed as means ± SEM (n = 6). ***P < 0.001 vs. WKY; ###P < 0.001 vs. 
SHR.
Table 2: Plasma levels of interleukin-1β (IL-1β), interleukin-6 (IL-6) and interleukin-10 (IL-10) in WKY, SHR, WKY treated 
with captopril (WKYCPT), and SHR treated with captopril (SHRCPT).
Parameter WKY SHR WKYCPT SHRCPT
IL-1β (pg/mL) 19.8 ± 1.2 32.3 ± 1.7*** 19.7 ± 0.8### 20.7 ± 1.8###
IL-6 (pg/mL) 81.7 ± 1 112.4 ± 7** 65.7 ± 1.6### 77 ± 6.5###
IL-10 (pg/mL) 57.5 ± 2.3 26.2 ± 0.9*** 49.3 ± 1.7### 45 ± 3.3**,###
Values are expressed as means ± SEM (n = 6). **P < 0.01, ***P < 0.001 vs. WKY; ###P < 0.001 vs. SHR.
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NADPH oxidase and a reduced activation of NF-κB.
At the end of the treatment period, we observed an
increase in blood pressures and in the heart rate in SHR
when compared with WKY rats, as expected from previ-
ous observations [34-37]. The high levels of blood pres-
sure and heart rate were accompanied by increases in the
relative left ventricle weight and in plasma levels of both
IL-1β and IL-6, and also by a reduction in the plasma lev-
els of IL-10. An increase in circulating pro-inflammatory
markers has been found in hypertensive patients [38] and
in patients with pulmonary arterial hypertension [39], as
well as in SHR [40], and in NO-deficient rats [8]. In con-
trast, a decrease in plasma levels of IL-10 has been found
in patients with coronary artery disease and arterial
hypertension [41], and in patients with pulmonary arte-
rial hypertension [39]. In addition, IL-10 prevented the
development of monocrotaline-induced pulmonary arte-
rial hypertension in rats [42]. The observed changes in
plasma levels of inflammatory markers in SHR were also
accompanied by similar alterations in the left ventricle
mRNA expression of these cytokines. These results are in
agreement with previous studies showing that cardiac
hypertrophy is associated with an inflammatory process
in the myocardium of SHR [7,16] and other models of
hypertension rats [8,17]. Moreover, the mRNA expres-
sion of IL-1β and IL-6 [40], intercellular/vascular cell
adhesion molecules (ICAM, VCAM) and monocyte
chemoattractant protein (MCP-1), have been reported to
be enhanced in aortas of hypertensive rats [18,40], and in
cardiac tissue from different rat models of hypertension
[5,43]. However, to our knowledge, this is the first evi-
dence concerning the decrease in plasma levels and left
ventricle mRNA expression of IL-10 in hypertensive ani-
mals. Previous work has proven that endogenous IL-10
limits angiotensin II (ANG II)-mediated oxidative stress,
inflammation and vascular dysfunction both in vivo and
in vitro, suggesting a protective action of IL-10 in vascu-
lar diseases such as arterial hypertension [14]. In fact, IL-
10 attenuates the increases in vascular superoxide and
endothelial dysfunction during diabetes and atheroscle-
Figure 1 RNA expression of interleukin-1β (A), interleukin-6 (B) 
and interleukin-10 (C) in WKY, SHR, WKY treated with captopril 
(WKYCPT) and SHR treated with captopril (SHRCPT). Values are ex-
pressed as means ± SEM (n = 6). The quantitative fold changes in 
mRNA expression were determined as relative to GAPDH mRNA levels 
in each corresponding group and calculated using the 2-ΔΔCT method. 
***P < 0.001 vs. WKY; ###P < 0.001 vs. SHR.
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Figure 2 RNA expression of angiotensin I converting enzyme, 
ACE (A), angiotensin II type I receptor, AT1R (B) and p22phox (C) 
in WKY, SHR, WKY treated with captopril (WKYCPT) and SHR 
treated with captopril (SHRCPT). Values are expressed as means ± 
SEM (n = 6). The quantitative fold changes in mRNA expression were 
determined as relative to GAPDH mRNA levels in each corresponding 
group and calculated using the 2-ΔΔCT method. ***P < 0.001 vs. WKY; ##P 
< 0.01, ###P < 0.001 vs. SHR.
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IL-10 might be a mediator of cardiac protection against
arterial hypertension.
The administration of captopril was able to prevent the
increase in blood pressures and heart rate observed in
SHR and reversed the enhancement in the left ventricle
weight index completely. These results are in agreement
with previous studies using SHR [16,46], NO-deficient
hypertensive rats [47] and obese Zucker rats, a model of
non-insulin-dependent diabetic hypertensive rats [48]. In
addition, when captopril was chronically administered,
the observed alterations in hypertensive animals regard-
ing plasma levels and left ventricle mRNA expression of
inflammatory cytokines disappeared, the values reaching
levels similar to those observed in WKY rats. In a previ-
ous work, enalapril (another ACE inhibitor) was able to
produce an increase in plasma levels of IL-10 in patients
with coronary artery disease and arterial hyperten-
sion[41]. Therefore, these results suggest an anti-inflam-
matory, cardioprotective effect of captopril in arterial
hypertension, with a reduction in the circulating pro-
inflammatory markers and an increase in those anti-
inflammatory cytokines; these effects result in a benefit
on the myocardial inflammatory process associated to
arterial hypertension.
This anti-inflammatory effect of captopril has been
previously proved in other diseases characterized by an
increase in the inflammation process, such as nephropa-
thy [26], arthritis [27], colitis [28] and uveitis [29]. More-
over, captopril produced a reduction in the inflammatory
cell infiltration in the left ventricle of rats with angio-
tensin II and aldosterone-salt-induced hypertension
[23,32].
Since several studies have shown the role of ANGII in
the beneficial effect of captopril in arterial hypertension
[30,49], more studies were designed in order to under-
stand the mechanisms involved in the anti-inflammatory
properties of captopril in the left ventricle of SHR. Our
results indicate that captopril might act via interfering
with NF-kB pathway activation, most probably by block-
ing the ANGII II production in the left ventricle of hyper-
tensive animals. We found that captopril was able to
prevent the increase in the left ventricle expression of
ACE and AT1R observed in SHR, leading to a decrease in
the local production and effect of ANGII. Bolterman et
al. [34] previously observed an increase in ANGII levels
in plasma of SHR when compared with WKY rats, which
was corrected after the treatment with captopril. In addi-
tion, a specific down-regulation of ACE and AT1R by
captopril has been also demonstrated in human dendritic
cells [50] and in aorta and heart tissue of fructose-fed rats
[51], respectively.
ANGII stimulates various signalling pathways that lead
to NF-kB activation [11,52]. Thus, ANGII stimulates
NADPH oxidase, which generates reactive oxygen species
(ROS), and ROS are involved as second messengers in
NF-κB activation and cytokine expression [53]. NF-κB
plays a crucial role regulating at the transcriptional level
several pro-inflammatory genes [6]. ANGII influences
NF-κB activation by stimulating the nuclear translocation
of the p65 subunit, DNA binding, transcription of a NF-
κB reporter gene and I-κB degradation. Conversely, NF-
κB stimulates the expression of the gene encoding angio-
tensinogen, thereby amplifying the ANGII-mediated
inflammatory process [54]. On the other hand, it has
been reported that a major role for IL-10 is to inhibit the
Figure 3 RNA expression of NF-κB (A) and IκB (B) in WKY, SHR, 
WKY treated with captopril (WKYCPT) and SHR treated with cap-
topril (SHRCPT). Values are expressed as means ± SEM (n = 6). The 
quantitative fold changes in mRNA expression were determined as rel-
ative to GAPDH mRNA levels in each corresponding group and calcu-
lated using the 2-ΔΔCT method. ***P < 0.001 vs. WKY; ###P < 0.001 vs. 
SHR.
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Figure 4 Nuclear factor-kappa (NF-κB) activity in nuclear extract 
of the left ventricle in WKY, SHR, WKY treated with captopril 
(WKYCPT) and SHR treated with captopril (SHRCPT). Values are ex-
pressed as means ± SEM (n = 6). **P < 0.01 vs. WKY; ##P < 0.01, ###P < 
0.001 vs. SHR.
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through an inactivation of NF-κB [55].
Numerous studies have shown that NF-kB participates
in the vascular, renal and cardiac inflammatory processes
in different models of arterial hypertension through its
ability to activate a variety of inflammation-mediating
genes. In experimental models of hypertension, the inhi-
bition of NF-kB prevented ANGII-induced expression of
IL-6, VCAM-1 and MCP-1, thus attenuating the inflam-
matory damage caused by ANGII [56,57].
The present study shows that the increase in the mRNA
expression of IL-1β and IL-6 and the decrease in the
mRNA expression of IL-10 in SHR is associated with an
abnormally high cardiac mRNA expression of both
p22phox (subunit of NADPH oxidase) and NF-κB, and a
lower expression of IκB (a molecule that inhibits the
translocation of NF-κB to the nucleus and its subsequent
activation). In addition, a higher activation of NF-κB has
been found in the left ventricle of hypertensive animals
when compared with WKY rats. These results are in
agreement with previous studies that reported an
increase in NF-κB expression in SHR aorta and left ven-
tricle [40,56], and also in the renal activation of NF-κB in
SHR and in salt-sensitive hypertension [4,58].
When captopril was administered to hypertensive rats,
the decrease in mRNA expression of pro-inflammatory
markers and the increase in the expression of anti-inflam-
matory cytokine were accompanied by a reduction in the
gene expression of p22phox and NF-κB, and by an
increase in that of IκB. Moreover, captopril was able to
reverse the activation of NF-κB found in left ventricle of
SHR. These results suggest an inactivation of the NF-κB
system in the beneficial effect of captopril in hyperten-
sion-induced cardiac damage. A decrease in the gene
expression of NF-κB has been observed in aortas of SHR
treated with the AT1R blocker, candesartan [59], and
inactivation of NF-κB has been found in aortas of rats
infused with ANGII and then treated with losartan [60];
in macrophages and vascular smooth muscle cells from a
rabbit model of atherosclerosis after the treatment with
quinapril [19]; in the kidney cortex of rats with unilateral
urethral obstruction treated with enalapril [61], and in
captopril-treated uveitis [29]. In contrast, no changes in
the protein expression of NF-κB was reported in the left
ventricle of captopril-treated SHR[4].
It has been proposed that an increased superoxide pro-
duction contributes to the development of hypertension
via activation of the sympathetic nervous system [62].
The presence of changes in heart rate in captopril-treated
rats suggests that the effect of sympathetic function
might play a major role in the antihypertensive effect of
this compound. Moreover, the anti-inflammatory effect
of captopril occurred together with a decrease in blood
pressure. It has been demonstrated that mechanical stress
induces reactive oxygen species formation via an up-reg-
ulation of NADPH oxidase [4,62]. Therefore, the
observed anti-inflammatory and cardiac effects of capto-
pril in SHR might be due not only to the inactivation of
RAS above mentioned, but also to a reduction of the
mechanical stress on the vessel wall.
Conclusions
Our findings show that captopril decreases the inflam-
mation process in the left ventricle of hypertensive rats
through a reduction in the activation of NF-κB-depen-
dent pro-inflammatory factors. Since the anti-inflamma-
tory effect of captopril occurred together with a
reduction in blood pressure and heart rate, it is possible
that a part of the observed anti-inflammatory and cardio-
protective effects of captopril might be due to the reduc-
tion in mechanical stress on the wall. Thus, it could be
proposed that both the inactivation of RAS and blood
pressure reduction are mechanisms accounting for the
anti-inflammatory effect of captopril in SHR.
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